BioStock: Curasight CEO reflects on a Q3 with strong progress

Curasight recently released its Q3 report, reflecting on a period of good momentum. Publishing complete phase II results with uTRACE in brain cancer, the company announced that the indication will be the target for a first-in-human trial with uTREAT. Following the oversubscribed rights issue in September, further funding for the study is added through the exercise of the TO 2 warrants. BioStock contacted CEO Ulrich Krasilnikoff for his thoughts.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/11/curasight-ceo-reflects-on-a-q3-with-strong-progress/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se